Head-to-Head Comparison of Nasopharyngeal, Oropharyngeal and Nasal Swabs for SARS-CoV-2 Molecular Testing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,03 MB, PDF-dokument

  • Kasper Daugaard Larsen
  • Mads Mose Jensen
  • Anne-Sophie Homøe
  • Elisabeth Arndal
  • Grethe Badsberg Samuelsen
  • Anders Koch
  • Xiaohui Chen Nielsen
  • Homøe, Preben
  • Todsen, Tobias

Nasopharyngeal swabs (NPS) are considered the gold standard for SARS-CoV-2 testing but are technically challenging to perform and associated with discomfort. Alternative specimens for viral testing, such as oropharyngeal swabs (OPS) and nasal swabs, may be preferable, but strong evidence regarding their diagnostic sensitivity for SARS-CoV-2 testing is still missing. We conducted a head-to-head prospective study to compare the sensitivity of NPS, OPS and nasal swabs specimens for SARS-CoV-2 molecular testing. Adults with an initial positive SARS-CoV-2 test were invited to participate. All participants had OPS, NPS and nasal swab performed by an otorhinolaryngologist. We included 51 confirmed SARS-CoV-2-positive participants in the study. The sensitivity was highest for OPS at 94.1% (95% CI, 87 to 100%) compared to NPS at 92.5% (95% CI, 85 to 99%) (p = 1.00) and lowest for nasal swabs at 82.4% (95% CI, 72 to 93%) (p = 0.07). Combined OPS/NPS was detected in 100% of cases, while the combined OPS/nasal swab increased the sensitivity significantly to 96.1% (95% CI, 90 to 100%) compared to that of the nasal swab alone (p = 0.03). The mean Ct value for NPS was 24.98 compared to 26.63 for OPS (p = 0.084) and 30.60 for nasal swab (p = 0.002). OPS achieved a sensitivity comparable to NPS and should be considered an equivalent alternative for SARS-CoV-2 testing.

OriginalsprogEngelsk
Artikelnummer283
TidsskriftDiagnostics
Vol/bind13
Udgave nummer2
Antal sider9
ISSN2075-4418
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This research received funding from the Novo Nordisk Foundation, Grant Number NNF21SA0069151. The sponsor had no role in planning, execution or analyzing the results of the study.

Publisher Copyright:
© 2023 by the authors.

ID: 387981743